TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30209851

Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 28012023

Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (MTX) administered via auto-injector into the abdomen (MTXAIab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (MTX) administered via auto-injector into the thigh (MTXAIth)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methotrexate (MTX)
Number of subjects: 0
Study: 26303560

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 110

Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 110
Study: 24516645

Group type: EXPERIMENTAL
Intervention: High frequency (HF) training
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Moderate frequency (MF) training
Number of subjects: 21
Study: 22943609

Group type: EXPERIMENTAL
Intervention: Six-month treatment program of pharmacotherapy, standardized patient and provider education, and physician and patient counseling
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 63
Study: 19962845

Group type: EXPERIMENTAL
Intervention: Tailored education-coaching (TEC) intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study: 17599629

Group type: EXPERIMENTAL
Intervention: epalrestat (50 mg/day p.o. ac, t.i.d.)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: epalrestat
Number of subjects: 603
Study: 16242556

Group type: EXPERIMENTAL
Intervention: Surgical embolectomy plus controlled reperfusion using a simplified perfusion system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Surgical embolectomy alone
Number of subjects: 15
Study: 12121014

Group type: EXPERIMENTAL
Intervention: Skin staplers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monofilament sutures
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 10450737

Group type: EXPERIMENTAL
Intervention: Laparoscopic preperitoneal mesh (TAPP)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Open preperitoneal mesh
Number of subjects: 613

Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 613
Study: 8695558

Group type: EXPERIMENTAL
Intervention: HLA A1, A33, B8, B47, B51, B53, B57, B62, DR3, DR12, DR13
Number of subjects: 128

Group type: COMPARATOR
Intervention: HLA B12, B17, DR2
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: HLA antigens
Number of subjects: 128
Study: 1804787

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Amoxycillin clavulanate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study: 6320400

Group type: EXPERIMENTAL
Intervention: Acupuncture on electrically detected points
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo acupuncture on 'placebo' points
Number of subjects: 30
Study: 31925451

Group type: EXPERIMENTAL
Intervention: Team-based learning
Number of subjects: 88

Group type: COMPARATOR
Intervention: Peer-assisted learning
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All groups (team-based, peer-assisted, conventional)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall course evaluation
Number of subjects: 88
Study: 31759465

Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list comparison group
Number of subjects: 0
Study: 29805066

Group type: EXPERIMENTAL
Intervention: Typical vascularization pattern (90% of specimens) with ascending palatine and ascending pharyngeal artery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Arterial variation (10% of specimens) with dependence on ascending pharyngeal artery alone
Number of subjects: 30
Study: 29871088

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 75
Study: 24746254

Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration with primary closure (group A)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Laparoscopic common bile duct exploration with T-tube drainage (group B)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Overall postoperative complications (group A)
Number of subjects: 194
Study: 21810288

Group type: EXPERIMENTAL
Intervention: Higher dose oat β‐glucan (3·0 g β‐glucan; oats high ‐ OH)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-dose oat β‐glucan (1·5 g β‐glucan; oats low ‐ OL)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Minimal β‐glucan (control)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Higher dose oat β‐glucan (3·0 g β‐glucan; oats high ‐ OH) in responders
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-dose oat β‐glucan (1·5 g β‐glucan; oats low ‐ OL) in responders
Number of subjects: 87

Group type: COMPARATOR
Intervention: Minimal β‐glucan (control) in responders
Number of subjects: 87
Study: 19602218

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study: 17875827

Group type: EXPERIMENTAL
Intervention: Freeze 24/7 Anti-Wrinkle Cream
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LiftFusion Micro-Injected M-Tox Transdermal Face Lift
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (Nutraderm Therapeutic Lotion)
Number of subjects: 42
Study: 15117834

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine challenge (DSMR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Delayed enhancement imaging with Gd-DTPA (SCAR)
Number of subjects: 29
Study: 11080606

Group type: EXPERIMENTAL
Intervention: Individual visit with a physician
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Physician visit plus a visit with a health educator
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Group visit of eight new members led by a physician and health educator
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 564
Study: 9846599

Group type: EXPERIMENTAL
Intervention: 200 mg oral caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (highly decaffeinated coffee)
Number of subjects: 30
Study: 9501808

Group type: EXPERIMENTAL
Intervention: Elective repair of asymptomatic AAA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for asymptomatic AAA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (trials ongoing)
Number of subjects: 0
Study: 2623040

Group type: EXPERIMENTAL
Intervention: Active marijuana (1.3‐2.7% delta 9‐THC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 892957

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg, three times daily for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30900025

Group type: EXPERIMENTAL
Intervention: Inoculation with arbuscular mycorrhizal fungi (AMF) - Rhizophagus irregularis or Funneliformis mosseae or a mixture of both species
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inoculation with Pseudomonas fluorescens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-inoculated controls
Number of subjects: 0
Study: 28087069

Group type: EXPERIMENTAL
Intervention: 2 mg/kg RG-101
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 4 mg/kg RG-101
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RG-101 (both dosages)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26076141

Group type: EXPERIMENTAL
Intervention: Prebiotics group (PG)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Breast-fed group (BG)
Number of subjects: 672
Study: 23816448

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (21 sessions, weekly)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard psychiatric care (including standard pharmacological treatment)
Number of subjects: 102
Study: 22117618

Group type: EXPERIMENTAL
Intervention: Individual lifestyle counselling by a physician (IG) every six months for 18 months
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Individual and interdisciplinary group-based program (IIG) over 16 weeks
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Combined IG and IIG
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 213
Study: 19687781

Group type: EXPERIMENTAL
Intervention: ABCC1 SNP rs4148382
Number of subjects: 2542

Group type: EXPERIMENTAL
Intervention: ABCC1 SNP rs212093
Number of subjects: 2542

Group type: EXPERIMENTAL
Intervention: ABCC1 SNP rs35621
Number of subjects: 2542
Study: 16371411

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² every 3 weeks (3W arm)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Docetaxel 36 mg/m² weekly (1W arm)
Number of subjects: 259
Study: 15482167

Group type: EXPERIMENTAL
Intervention: Thymalfasin (Talpha1) 1.6 mg twice-weekly for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thymalfasin (Talpha1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymalfasin (Talpha1) and interferon combination therapy
Number of subjects: 0
Study: 10906101

Group type: EXPERIMENTAL
Intervention: Mitomycin C application during DCR surgery (0.2 mg/ml for 30 minutes)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional DCR surgery
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mitomycin C application during DCR surgery
Number of subjects: 88
Study: 9289023

Group type: EXPERIMENTAL
Intervention: Supplemented enteral group (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enteral standard group (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Parenteral group (group 3)
Number of subjects: 30
Study: 8513961

Group type: EXPERIMENTAL
Intervention: 200 mg RU486 (single dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2426419

Group type: EXPERIMENTAL
Intervention: Vinblastine 0.4 mg/kg/cycle
Number of subjects: 214

Group type: COMPARATOR
Intervention: Vinblastine 0.3 mg/kg/cycle
Number of subjects: 214
Study: 29601488

Group type: EXPERIMENTAL
Intervention: Fruit smoothie
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fresh fruit equivalent of the smoothie
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Blackcurrant squash
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 47

Group type: COMPARATOR
Intervention: Water
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Energy-containing preloads (fruit smoothie, fresh fruit, blackcurrant squash, milk)
Number of subjects: 47
Study: 27588540

Group type: EXPERIMENTAL
Intervention: Self-reported substance use (alcohol and tobacco) in 12th grade
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Eligibility for free or reduced-price lunch in 6th grade
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Alcohol use in 6th grade
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Cigarette use in 12th grade
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Alcohol use in 12th grade
Number of subjects: 1044
Study: 23920211

Group type: EXPERIMENTAL
Intervention: Educational support group (viewed 2 consecutive polysomnograms)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard support group
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Educational support group
Number of subjects: 206
Study: 23272529

Group type: EXPERIMENTAL
Intervention: Adaptogens (multiple dose administration, twice daily) plus standard prevention protocol (lifestyle counseling)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard prevention protocol (lifestyle counseling) only
Number of subjects: 40
Study: 20660805

Group type: EXPERIMENTAL
Intervention: Performance improvement intervention
Number of subjects: 34810
Study: 18488880

Group type: EXPERIMENTAL
Intervention: Topical tazarotene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical retinoids (including tretinoin and isotretinoin)
Number of subjects: 0
Study: 16133397

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bone Scintigraphy
Number of subjects: 55
Study: 12236311

Group type: COMPARATOR
Intervention: K file using step‐back technique without coronal flaring (control; group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: K file using step‐back technique after coronal flaring (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LightSpeed instrumentation (group 3)
Number of subjects: 30
Study: 10441602

Group type: EXPERIMENTAL
Intervention: Continuation of immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment groups (continuation and discontinuation)
Number of subjects: 0
Study: 7801862

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (bolus dose followed by continuous infusion at 5, 10, and 15 mg/hour)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem at 5 mg/hour
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem at 10 mg/hour
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem at 15 mg/hour
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem (all doses)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem
Number of subjects: 84
Study: 2237752

Group type: COMPARATOR
Intervention: 10 Gy irradiation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 16 Gy irradiation
Number of subjects: 44
Study: 4392983

Group type: EXPERIMENTAL
Intervention: Practolol (200 to 600 mg b.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propranolol (80 mg q.d.s.)
Number of subjects: 15
Study: 31274345

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea (EVH) in the morning (AM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea (EVH) in the evening (PM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baseline FEV1 before AM tests
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baseline FEV1 before PM tests
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Minute ventilation in AM tests
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Minute ventilation in PM tests
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 30522886

Group type: EXPERIMENTAL
Intervention: PAP therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study: 29114763

Group type: EXPERIMENTAL
Intervention: Vocabulary instruction
Number of subjects: 241

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 241
Study: 26176342

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 24479361

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg (2 ml), intravenous injection, twice a day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline 2 ml, intravenous injection, twice a day (Control)
Number of subjects: 56
Study: 21263210

Group type: EXPERIMENTAL
Intervention: Gentle baby massage
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 42
Study: 19385962

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 98
Study: 16785142

Group type: EXPERIMENTAL
Intervention: Metformin 1.5 g/day + rFSH 150 UI/day + GnRH antagonist 0.25 mg/day
Number of subjects: 40
Study: 15116994

Group type: EXPERIMENTAL
Intervention: U‐shaped masking functions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotonic masking functions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental situation
Number of subjects: 0
Study: 11357500

Group type: EXPERIMENTAL
Intervention: 370 MBq DW-166HC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 555 MBq DW-166HC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 740 MBq DW-166HC
Number of subjects: 16
Study: 9408319

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (three field lymphadenectomy for esophageal cancer, D2 lymphadenectomy for gastric cancer)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Limited lymphadenectomy (D1)
Number of subjects: 25
Study: 8231902

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine oestrogens (CEE) cyclically (n = 16)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50 micrograms/day transdermal oestradiol (E2) cyclically (n = 20)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE continuously (n = 15)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE and 2.5 mg/day of MPA continuously (n = 20)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 90
Study: 3475969

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1,000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or no treatment not specified)
Number of subjects: 0
Study: 31444866

Group type: EXPERIMENTAL
Intervention: Multiple emulsion loaded with Sphaeranthus indicus flower extract
Number of subjects: 0
Study: 29105855

Group type: EXPERIMENTAL
Intervention: Dicloxacillin 1 g three times daily for 10 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dicloxacillin exposure in primary hepatocytes for 48 h
Number of subjects: 12
Study: 27259062

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 84
Study: 24879757

Group type: EXPERIMENTAL
Intervention: Zilpaterol hydrochloride (ZH; 8.3 mg/kg of DM for 20 d with 3‐d withdrawal)
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Ractopamine hydrochloride (RH; 308 mg·head(‐1)·d(‐1) for 28 d)
Number of subjects: 1914

Group type: COMPARATOR
Intervention: No βAA (CON)
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Consumer assessment of eating quality (n = 400; 200/postmortem aging period)
Number of subjects: 1914
Study: 23577826

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional monitoring (CM)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ILR
Number of subjects: 44

Group type: COMPARATOR
Intervention: CM
Number of subjects: 44
Study: 20488971

Group type: EXPERIMENTAL
Intervention: Especially for Daughters intervention (audio CDs mailed home)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Attention-controlled condition (print materials)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study: 19026795

Group type: EXPERIMENTAL
Intervention: Preoperative renal dysfunction
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Control (no preoperative renal dysfunction)
Number of subjects: 3014
Study: 16125252

Group type: EXPERIMENTAL
Intervention: Ionized, processed silicone tubes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Silicone tubes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Duration of ventilation tube application
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Biofilm growth
Number of subjects: 46
Study: 15070409

Group type: EXPERIMENTAL
Intervention: Veteran group (36 residents)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-veteran group (45 residents)
Number of subjects: 81
Study: 11412729

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 60
Study: 9008250

Group type: EXPERIMENTAL
Intervention: Sodium chloride supplementation (100 mmol/24 h)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sodium chloride restriction (60 to 80 mmol/24 h)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ad libitum sodium chloride
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sodium chloride restriction
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sodium chloride supplementation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sodium chloride restriction (open-label)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sodium chloride ad libitum (open-label)
Number of subjects: 99
Study: 8509523

Group type: EXPERIMENTAL
Intervention: Moclobemide (MAO inhibitor), fixed-dose schedule for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 3620290

Group type: EXPERIMENTAL
Intervention: Sulpiride (1 mg, 10 mg, 50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulpiride (chronic treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30827283

Group type: EXPERIMENTAL
Intervention: CATH TAG electronic reminder system
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Control group (no CATH TAG)
Number of subjects: 1167
Study: 29379865

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at 20 Hz on the left prefrontal area
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) at 5 Hz, 10 Hz, and 40 Hz
Number of subjects: 0
Study: 25601623

Group type: EXPERIMENTAL
Intervention: Multi-moment non-invasive neurostimulation (MNNS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: International Affective Pictures System (IAPS)
Number of subjects: 33
Study: 24061387

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral intervention (5-week duration)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral intervention
Number of subjects: 228
Study: 21420678

Group type: EXPERIMENTAL
Intervention: IKH‐01 (0.035 mg ethinyl estradiol and 1 mg norethisterone)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: IKH‐01
Number of subjects: 115